- Home
- RSLS vs XBIO Comparison
RSLS vs XBIO Comparison
Compare RSLS & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- XBIO
- Stock Information
- Founded
- RSLS 2002
- XBIO N/A
- Country
- RSLS United States
- XBIO United States
- Employees
- RSLS N/A
- XBIO N/A
- Industry
- RSLS Medical/Dental Instruments
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RSLS Health Care
- XBIO Health Care
- Exchange
- RSLS Nasdaq
- XBIO Nasdaq
- Market Cap
- RSLS 4.5M
- XBIO 4.2M
- IPO Year
- RSLS 2007
- XBIO N/A
- Fundamental
- Price
- RSLS $2.39
- XBIO $4.08
- Analyst Decision
- RSLS Hold
- XBIO Hold
- Analyst Count
- RSLS 1
- XBIO 1
- Target Price
- RSLS N/A
- XBIO N/A
- AVG Volume (30 Days)
- RSLS 4.4M
- XBIO 187.9K
- Earning Date
- RSLS 08-13-2025
- XBIO 08-12-2025
- Dividend Yield
- RSLS N/A
- XBIO N/A
- EPS Growth
- RSLS N/A
- XBIO N/A
- EPS
- RSLS N/A
- XBIO N/A
- Revenue
- RSLS $7,175,000.00
- XBIO $2,582,728.00
- Revenue This Year
- RSLS $52.80
- XBIO $14.23
- Revenue Next Year
- RSLS N/A
- XBIO $7.14
- P/E Ratio
- RSLS N/A
- XBIO N/A
- Revenue Growth
- RSLS N/A
- XBIO 5.63
- 52 Week Low
- RSLS $2.23
- XBIO $2.20
- 52 Week High
- RSLS $347.86
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- RSLS 38.10
- XBIO 61.16
- Support Level
- RSLS $2.37
- XBIO $3.44
- Resistance Level
- RSLS $2.73
- XBIO $4.46
- Average True Range (ATR)
- RSLS 0.17
- XBIO 0.63
- MACD
- RSLS 0.21
- XBIO 0.05
- Stochastic Oscillator
- RSLS 13.33
- XBIO 54.79
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.